Revelation Biosciences, Inc.
REVB
$3.40
$0.061.80%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.27% | 10.13% | 8.22% | 44.11% | 37.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.32% | 30.49% | 17.43% | 90.91% | 131.59% |
| Operating Income | 35.32% | -30.49% | -17.43% | -90.91% | -131.59% |
| Income Before Tax | 14.72% | -479.33% | -143.53% | -82.42% | -124.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.72% | -479.33% | -143.53% | -82.42% | -124.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.72% | -479.33% | -143.53% | -82.42% | -124.52% |
| EBIT | 35.32% | -30.49% | -17.43% | -90.91% | -131.59% |
| EBITDA | 35.43% | -30.54% | -17.50% | -91.37% | -132.28% |
| EPS Basic | 91.58% | 12.01% | 50.83% | -66.40% | -- |
| Normalized Basic EPS | 91.58% | 12.01% | -- | -66.40% | -- |
| EPS Diluted | 91.55% | 12.01% | 50.92% | -66.12% | -- |
| Normalized Diluted EPS | 91.58% | 12.01% | -- | -66.40% | -- |
| Average Basic Shares Outstanding | 915.15% | 559.35% | -- | 9.27% | -- |
| Average Diluted Shares Outstanding | 915.15% | 559.35% | 350.99% | 9.27% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
